CoChat
Sign Up
Cited by 222

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human

Mir, Rafeeq, Tonelli, Francesca, Lis, Pawel, Macartney, Thomas, Polinski, Nicole K., Martinez, Terina N., Chou, Meng-Yun, Howden, Andrew J.M., König, Theresa, Hotzy, Christoph, Milenkovic, Ivan, Brücke, Thomas, Zimprich, Alexander, Sammler, Esther, Alessi, Dario R.·2018·Biochemical Journal
DOI 10.1042/bcj20180248PMC PMC5989534
Open this paper in CoChat — free account

Abstract

Missense mutations in the LRRK2 (Leucine-rich repeat protein kinase-2) and VPS35 genes result in autosomal dominant Parkinson's disease. The VPS35 gene encodes for the cargo-binding component of the retromer complex, while LRRK2 modulates vesicular trafficking by phosphorylating a subgroup of Rab proteins. Pathogenic mutations in LRRK2 increase its kinase activity. It is not known how the only thus far described pathogenic VPS35 mutation, [p.D620N] exerts its effects. We reveal that the VPS35[D620N] knock-in mutation strikingly elevates LRRK2-mediated phosphorylation of Rab8A, Rab10, and Rab12 in mouse embryonic fibroblasts. The VPS35[D620N] mutation also increases Rab10 phosphorylation in mouse tissues (the lung, kidney, spleen, and brain). Furthermore, LRRK2-mediated Rab10 phosphorylation is increased in neutrophils as well as monocytes isolated from three Parkinson's patients with a heterozygous VPS35[D620N] mutation compared with healthy donors and idiopathic Parkinson's patients. LRRK2-mediated Rab10 phosphorylation is significantly suppressed by knock-out or knock-down of VPS35 in wild-type, LRRK2[R1441C], or VPS35[D620N] cells. Finally, VPS35[D620N] mutation promotes Rab10 phosphorylation more potently than LRRK2 pathogenic mutations. Available data suggest that Parkinson's patients with VPS35[D620N] develop the disease at a younger age than those with LRRK2 mutations. Our observations indicate that VPS35 controls LRRK2 activity and that the VPS35[D620N] mutation results in a gain of function, potentially causing PD through hyperactivation of the LRRK2 kinase. Our findings suggest that it may be possible to elaborate compounds that target the retromer complex to suppress LRRK2 activity. Moreover, patients with VPS35[D620N] associated Parkinson's might benefit from LRRK2 inhibitor treatment that have entered clinical trials in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bcj20180248

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03 · DOI
  2. Domingo, 2018, Genetics of Parkinson disease, Handb. Clin. Neurol., 147, 211, 10.1016/B978-0-444-63233-3.00014-2 · DOI
  3. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI
  4. Paisán-Ruı´z, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 · DOI
  5. Alessi, 2018, LRRK2 kinase in Parkinson's disease, Science, 360, 36, 10.1126/science.aar5683 · DOI · Paper page
  6. Bardien, 2011, Genetic characteristics of Leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease, Parkinsonism. Relat. Disord., 17, 501, 10.1016/j.parkreldis.2010.11.008 · DOI
  7. Cookson, 2010, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, Nat. Rev. Neurosci., 11, 791, 10.1038/nrn2935 · DOI
  8. Purlyte, 2018, Rab29 activation of the Parkinson's disease-associated LRRK2 kinase, EMBO J., 37, 1, 10.15252/embj.201798099 · DOI · Paper page
  9. Liu, 2018, LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network, Hum. Mol. Genet., 27, 385, 10.1093/hmg/ddx410 · DOI · Paper page
  10. Fujimoto, 2018, Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology, Biochem. Biophys. Res. Commun., 495, 1708, 10.1016/j.bbrc.2017.12.024 · DOI
  11. Steger, 2016, Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases, eLife, 5, 809, 10.7554/eLife.12813 · DOI · Paper page
  12. Steger, 2017, Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis, eLife, 6, e80705, 10.7554/eLife.31012 · DOI · Paper page
  13. Hutagalung, 2011, Role of Rab GTPases in membrane traffic and cell physiology, Physiol. Rev., 91, 119, 10.1152/physrev.00059.2009 · DOI · Paper page
  14. Pfeffer, 2013, Rab GTPase regulation of membrane identity, Curr. Opin. Cell Biol., 25, 414, 10.1016/j.ceb.2013.04.002 · DOI
  15. Jeong, 2018, Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration, Mol. Neurodegener., 13, 8, 10.1186/s13024-018-0240-1 · DOI
  16. Schaub, 2013, The Rilp-like proteins Rilpl1 and Rilpl2 regulate ciliary membrane content, Mol. Biol. Cell, 24, 453, 10.1091/mbc.e12-08-0598 · DOI
  17. Ito, 2016, Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors, Biochem. J., 473, 2671, 10.1042/BCJ20160557 · DOI · Paper page
  18. Lis, 2018, Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase, Biochem. J., 475, 1, 10.1042/BCJ20170802 · DOI · Paper page
  19. Kiral, 2018, Rab GTPases and membrane trafficking in neurodegeneration, Curr. Biol., 28, R471, 10.1016/j.cub.2018.02.010 · DOI
  20. Gao, 2018, The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease, Mov. Disord., 33, 196, 10.1002/mds.27270 · DOI
  21. Lai, 2015, Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1, EMBO J., 34, 2840, 10.15252/embj.201591593 · DOI
  22. Cooper, 2006, α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models, Science, 313, 324, 10.1126/science.1129462 · DOI
  23. Roosen, 2016, LRRK2 at the interface of autophagosomes, endosomes and lysosomes, Mol. Neurodegener., 11, 73, 10.1186/s13024-016-0140-1 · DOI
  24. Deng, 2013, The VPS35 gene and Parkinson's disease, Mov. Disord., 28, 569, 10.1002/mds.25430 · DOI
  25. Zimprich, 2011, A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease, Am. J. Hum. Genet., 89, 168, 10.1016/j.ajhg.2011.06.008 · DOI · Paper page
  26. Vilariño-Güell, 2011, VPS35 mutations in Parkinson disease, Am. J. Hum. Genet., 89, 162, 10.1016/j.ajhg.2011.06.001 · DOI · Paper page
  27. Williams, 2017, VPS35, the retromer complex and Parkinson's disease, J. Parkinsons's Dis., 7, 219, 10.3233/JPD-161020 · DOI
  28. Sharma, 2012, A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants, J. Med. Genet., 49, 721, 10.1136/jmedgenet-2012-101155 · DOI
  29. Hierro, 2007, Functional architecture of the retromer cargo-recognition complex, Nature, 449, 1063, 10.1038/nature06216 · DOI · Paper page
  30. MacLeod, 2013, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk, Neuron, 77, 425, 10.1016/j.neuron.2012.11.033 · DOI · Paper page
  31. Linhart, 2014, Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2), Mol. Neurodegener., 9, 23, 10.1186/1750-1326-9-23 · DOI
  32. Inoshita, 2017, Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in drosophila, Hum. Mol. Genet., 26, 2933, 10.1093/hmg/ddx179 · DOI · Paper page
  33. Fell, 2015, MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition, J. Pharmacol. Exp. Ther., 355, 397, 10.1124/jpet.115.227587 · DOI
  34. Scott, 2017, Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity, J. Med. Chem., 60, 2983, 10.1021/acs.jmedchem.7b00045 · DOI
  35. Reith, 2012, GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor, Bioorg. Med. Chem. Lett., 22, 5625, 10.1016/j.bmcl.2012.06.104 · DOI
  36. Henderson, 2015, Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7 H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor, J. Med. Chem., 58, 419, 10.1021/jm5014055 · DOI
  37. Spieker-Polet, 1995, Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas, Proc. Natl Acad. Sci. U.S.A., 92, 9348, 10.1073/pnas.92.20.9348 · DOI
  38. Pytela, 2008, Fusion partner for production of monoclonal rabbit antibodies, United States patent., 7, 429
  39. Dzamko, 2012, The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during toll-like receptor signaling, PLoS ONE, 7, e39132, 10.1371/journal.pone.0039132 · DOI
  40. Wiggin, 2002, MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts, Mol. Cell. Biol., 22, 2871, 10.1128/MCB.22.8.2871-2881.2002 · DOI
  41. Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein, Neuron, 64, 807, 10.1016/j.neuron.2009.11.006 · DOI
  42. Fan, 2018, Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils, Biochem. J., 475, 23, 10.1042/BCJ20170803 · DOI · Paper page
  43. Ishizu, 2016, Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice, Hum. Mol. Genet., 25, 4507, 10.1093/hmg/ddw279 · DOI
  44. Munsie, 2015, Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N, Hum. Mol. Genet., 24, 1691, 10.1093/hmg/ddu582 · DOI · Paper page
  45. Tsika, 2014, Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration, Hum. Mol. Genet., 23, 4621, 10.1093/hmg/ddu178 · DOI · Paper page
  46. Zavodszky, 2014, Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy, Nat. Commun., 5, 3828, 10.1038/ncomms4828 · DOI · Paper page
  47. Dzamko, 2010, Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization, Biochem. J., 430, 405, 10.1042/BJ20100784 · DOI
  48. Sheng, 2012, Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations, Sci. Transl. Med., 4, 164ra161, 10.1126/scitranslmed.3004485 · DOI
  49. Rieckmann, 2017, Social network architecture of human immune cells unveiled by quantitative proteomics, Nat. Immunol., 18, 583, 10.1038/ni.3693 · DOI
  50. Jimenez-Orgaz, 2018, Control of RAB7 activity and localization through the retromer-TBC1D5 complex enables RAB7-dependent mitophagy, EMBO J., 37, 235, 10.15252/embj.201797128 · DOI · Paper page
  51. Kondapalli, 2012, PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65, Open Biol., 2, 120080, 10.1098/rsob.120080 · DOI · Paper page
  52. Beilina, 2014, Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease, Proc. Natl Acad. Sci. U.S.A., 111, 2626, 10.1073/pnas.1318306111 · DOI · Paper page
  53. Pihlstrøm, 2015, Fine mapping and resequencing of the PARK16 locus in Parkinson's disease, J. Hum. Genet., 60, 357, 10.1038/jhg.2015.34 · DOI · Paper page
  54. Kuwahara, 2016, LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts, Sci. Rep., 6, 29945, 10.1038/srep29945 · DOI · Paper page
  55. Lill, 2016, Launching the movement disorders society genetic mutation database (MDSGene), Mov. Disord., 31, 607, 10.1002/mds.26651 · DOI
  56. Lee, 2017, Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry, Mov. Disord., 32, 1432, 10.1002/mds.27059 · DOI
  57. Ferreira, 2007, High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal, Mov. Disord., 22, 1194, 10.1002/mds.21525 · DOI
  58. Yescas, 2010, Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease, Neurosci. Lett., 485, 79, 10.1016/j.neulet.2010.08.029 · DOI
  59. Gorostidi, 2009, LRRK2 g2019s and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity, Neurogenetics, 10, 157, 10.1007/s10048-008-0162-0 · DOI
  60. Meixner, 2011, A QUICK screen for Lrrk2 interaction partners — leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics, Mol. Cell. Proteomics, 10, M110.001172, 10.1074/mcp.M110.001172 · DOI
  61. McGough, 2014, Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation, Curr. Biol., 24, 1670, 10.1016/j.cub.2014.06.024 · DOI · Paper page
  62. West, 2017, Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease, Exp. Neurol., 298, 236, 10.1016/j.expneurol.2017.07.019 · DOI
  63. Hatcher, 2017, Small-molecule inhibitors of LRRK2, Adv. Neurobiol., 14, 241, 10.1007/978-3-319-49969-7_13 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., Chou, M.-Y., Howden, A. J. M., König, T., Hotzy, C., Milenkovic, I., Brücke, T., Zimprich, A., Sammler, E., & Alessi, D. R.
Affiliations
  • MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
  • The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, PO Box 4777, New York, NY 10163, U.S.A.
  • Abcam, 863 Mitten Rd, Burlingame, CA 94010, U.S.A.
  • Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, U.K.
  • Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria
  • Verein zur Förderung der wissenschaftlichen Forschung im, Wilhelminenspital (FWFW), Montleartstrasse 37, 1160 Wien, Austria
Venue
Biochemical Journal
Publisher
Portland Press Ltd.
Published
2018-06-06
Volume
475
Issue
11
Pages
1861-1883
ISSN
  • 0264-6021
  • 1470-8728
DOI
10.1042/bcj20180248
PMC
PMC5989534
Cited by
222
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 414 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review